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Long QT syndrome (LQTS): Although Outcomes 
Have Improved, 1 in 4 Patients with Prior 
Symptoms Experience at Least 1 Subsequent, Albeit 
Nonlethal, Cardiac Event Demanding Further 
Optimization of Treatment Strategies  
Among 606 patients with LQTS (LQT1 in 47%, 
LQT2 in 34%, and LQT3 in 9%), a potentially lethal 
cardiac channelopathy with a 1-5% annual risk of 
LQTS-triggered syncope, aborted cardiac arrest, or 
sudden cardiac death, there were 166 (27%) patients 
who were symptomatic prior to their first Mayo Clinic 
evaluation at a median age of 12 years at first symptom. 
Treatment strategies included no active therapy in 47 
(8%) patients, beta-blockers alone in 350 (58%) 
patients, ICDs alone in 25 (4%) patients, left cardiac 
sympathetic denervation alone in 18 (3%) patients, and 
combination therapy in 166 (27%) patients. Over a 
median follow-up of 6.7 years, 556 (92%) patients did 
not experience a cardiac event. Only 8 of 440 (2%) 
previously asymptomatic patients experienced a single 
event. In contrast, 42 of 166 (25%) previously 
symptomatic patients experienced >1 events. Among 
the 30 patients with >2 events, 2 patients died and 3 
LQT3 patients underwent cardiac transplantation 
(Rohatgi RK et al, J Am Coll Cardiol 2017;70:453–62).   
TRAC-AF Study: Temperature-Controlled Irrigated 
Ablation Produces Rapid, Efficient, and Durable PV 
Isolation  
A novel irrigated RF catheter (DiamondTemp -DT) 
designed with a diamond-embedded tip (for rapid cooling) 
and thermocouples to monitor tissue temperature, was first 
used in 6 pigs for atrial ablation in a temperature control 
mode (60°C/50 W) until there was ∼80% EGM amplitude 
reduction; lesion histology revealed transmurality in 51 of 
55 lesions (92.7%). In a clinical feasibility study, the study 
group of 35 patients having PV isolation with the DT 
catheter, compared with a control group of 35 patients 
undergoing PV isolation with a standard force-sensing 
catheter, had shorter mean RF application duration (26.3 ± 
5.2 min vs. 89.2 ± 27.2 min; p < 0.001), shorter mean 
fluoroscopic time (11.2 ± 8.5 min vs. 19.5 ± 6.8 min; p < 
0.001), and lower acute dormant PV reconduction (0 of 35 
vs. 5 of 35; p = 0.024). At 3 months, among 23 patients 
undergoing remapping, 39 of 46 PV pairs (84.8%) 
remained durably isolated in 17 of these patients (73.9%) 
(Iwasawa J et al, J Am Coll Cardiol 2017;70:542-553).   
Elevated Cardiac Troponin Concentration, Well 
Within the Normal Range, is Associated With an 
Increased Risk of Incident Cardiovascular Disease 
(CVD) Outcomes in the General Population 
In the PROSPER trial, hs-cTnT was detectable in 3,853 
(87.5%) of 4,402 participants and positive associations 
were observed between hs-cTnT and CVD outcomes. In a 
meta-analysis of 28 studies involving 154,052 participants, 
cardiac troponin was detectable in 80% (hs-cTnI: 82.6%; 
hs-cTnT: 69.7%), and the relative risks comparing the top 
vs the bottom troponin third were 1.43 for CVD (11,763 
events), 1.67 for fatal CVD (7,775 events), 1.59 for CHD 
(7,061 events), and 1.35 for stroke (2,526 events) (Willeit 
P et al, J Am Coll Cardiol 2017;70: :558–568).   
Patients With a New Diagnosis of Cancer Face an 
Increased Risk of Arterial Thromboembolism, 
Especially During the First 6 Months After Diagnosis  
Among 279,719 pairs of patients with cancer and 
matched control patients, the 6-month cumulative 
incidence of arterial thromboembolism was 4.7% in 
patients with cancer compared with 2.2% in control 
patients (hazard ratio - HR: 2.2). The 6-month cumulative 
incidence of myocardial infarction was 2% in patients with 
cancer compared with 0.7% in control patients (HR: 2.9). 
The 6-month cumulative incidence of ischemic stroke was 
3% in patients with cancer compared with 1.6% in control 
patients (HR: 1.9). Excess risk varied by cancer type 
(greatest for lung), correlated with cancer stage, and 
generally had resolved by 1 year (Navi BB et al, J Am Coll 
Cardiol 2017;70:926-938).   
In Patients with Non-Ischemic Cardiomyopathy 
(NICM), CRT-D was superior to CRT-P, Particularly 
in Patients with LV Midwall Fibrosis (MWF), which 
Emerged as an Independent Predictor of Mortality and 
Morbidity in Patients with NICM Undergoing CRT   
Among NICM patients with (+) (n=68) or without (−) 
left ventricular midwall fibrosis (MWF) (n=184), detected 
by cardiac magnetic resonance, +MWF emerged as an 
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independent predictor of total mortality (adjusted hazard 
ratio-HR: 2.31), total mortality or heart failure hospitaliza-
tion (HR: 2.02), total mortality or hospitalization for major 
adverse cardiac events (HR: 2.02), death from pump 
failure (HR: 1.95), and sudden cardiac death (HR: 3.75) 
over a maximum follow-up period of 14 years (median 3.8 
years for +MWF and 4.6 years for −MWF). In separate 
analyses of +MWF and −MWF, total mortality (HR: 0.23), 
total mortality or heart failure hospitalization (HR: 0.32), 
and total mortality or hospitalization for major adverse 
cardiac events (HR: 0.30) were lower after CRT-D than 
after CRT-P in +MWF but not in −MWF (Leyva F et al, J 
Am Coll Cardiol 2017;70:1216-1227).  
In Patients With Atrial Fibrillation (AF), More Severe 
Left Atrial (LA) Late Gadolinium Enhancement (LGE) 
was Associated With Increased Risk of Major Adverse 
Cardiovascular/Cerebrovascular Events (MACCE)  
Among 1,228 AF patients who underwent LGE–
cardiac MRI to quantify LA fibrosis, there occurred 62 
strokes or TIAs, 42 MIs, 156 HF events, and 38 CV deaths. 
In disease risk score (DRS) stratified analysis, the hazard 
ratio comparing patients with advanced stage vs early stage 
LA LGE was 1.67 for the MACCE outcome. The only 
individual component of the MACCE outcome to remain 
significantly associated with advanced LGE following 
DRS stratification was stroke or TIA (hazard ratio: 3.94 
(King JB et al, J Am Coll Cardiol 2017;70: 1311-1321).   
The Danish Diet, Cancer, and Health Study: Moderate 
Chocolate Intake May be Inversely Associated With 
Atrial Fibrillation (AF) Risk (11–20% Lower Rate)  
Among 55,502 participants (26,400 men / 29,102 
women) aged 50–64 years, during a median of 13.5 years 
there were 3346 AF cases. Compared with chocolate 
intake <once per month, the rate of AF was lower for 
people consuming 1–3 servings/month (hazard ratio -HR 
0.90), 1 serving/week (HR 0.83), 2–6 servings/week (HR 
0.80) and ≥1 servings/day (HR 0.84; p-linear trend 
<0.0001), with similar results for men and women 
(Mostofsky E et al, Heart 2017; 103:1163-1167).  
 
ADHERENCE Trial: In Patients With High-Dose 
Statin Intolerance, Combined Low-Dose Statin (LDS) 
and Nutraceuticals (Armolipid Plus) Were Efficacious 
Low-dose statin (LDS) therapy vs combined therapy of 
LDS plus a nutraceutical containing red yeast rice, 
policosanol, berberine, folic acid, coenzyme Q10 and 
astaxanthin (Armolipid Plus) was tested in 100 participants 
having undergone PCI who were high-dose statin 
intolerant. After 3 months, patients in the LDS +  
Armolipid Plus (n = 50) group had a greater reduction of 
LDL-C and total cholesterol (p <0.0001), and 70% 
achieved the therapeutic target (LDL-C <70 mg/dl). Six 
patients (3 from each group) dropped out due to myalgia 
(Marazzi G et al, Am J Cardiol 2017; 120:893-7).   
SWEDEHEART Registry: In Type 1 Diabetes (T1D) 
Patients With Multivessel Coronary Artery Disease, 
CABG was Associated With a Lower Risk of Coronary 
Mortality, MI, and Repeat Revascularization 
Compared With PCI  
Among 683 patients who underwent CABG and 1,863 
patients who underwent PCI, over a mean of 10.6 years, 
53% of patients in the CABG group and 45% in the PCI 
group died. PCI, compared with CABG, was associated 
with a similar risk of all-cause mortality (HR: 1.14), but 
higher risks of death from coronary disease (HR: 1.45), MI 
(HR: 1.47), and repeat revascularization (HR: 5.64). No 
differences in risks of stroke or heart failure were found 
(Nystrom T et al, J Am Coll Cardiol 2017;70:1441-1451).  
 
Diabetes does not Adversely Influence the Long-term 
Patency of Coronary Artery Bypass Grafts / Internal 
Mammary Artery Grafts have Excellent Patency in 
Patients with and without Diabetes Even 20 Years Post-
operatively  
Long-term graft patency was evaluated in 57,961 
patients with and without diabetes, who underwent 
primary isolated coronary artery bypass grafting (CABG). 
Internal mammary artery (IMA) graft patency was stable 
over time and similar in patients with and without diabetes 
at 1, 5, 10, and 20 years, 97%, 97%, 96%, and 96% in 
patients with diabetes, and 96%, 96%, 95%, and 93% in 
patients without diabetes, respectively (early p = 0.20; late 
p = 0.30). In contrast, saphenous vein graft (SVG) patency 
declined over time and similarly in patients with and 
without diabetes: at 1, 5, 10, and 20 years, 78%, 70%, 57%, 
and 42% in patients with diabetes, and 82%, 72%, 58%, 
and 41% in patients without diabetes, respectively (early p 
< 0.002; late p=0.60). The authors concluded that diabetes 
did not influence long-term patency of bypass grafts with 
excellent patency of IMA documented in patients with and 
without diabetes even after 20 years (Raza S et al, J Am 
Coll Cardiol 2017; 70:515-24).    
FRAILTY-AVR Study: Assessment of Frailty Using a 
Brief 4-Item Scale Encompassing Lower-Extremity 
Weakness, Cognitive Impairment, Anemia, and 
Hypoalbuminemia Adds Incremental Prognostic Value  
The incremental predictive value of 7 different frailty 
scales to predict poor outcomes following TAVI or 
surgical AVR was tested in 1,020 patients with a median 
age of 82 years. Depending on the scale used, the 
prevalence of frailty ranged from 26% to 68%. Frailty as 
measured by the Essential Frailty Toolset (EFT) was the 
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strongest predictor of death at 1 year (adjusted odds ratio -
OR: 3.72) with a C-statistic improvement of 0.071 (p < 
0.001) and integrated discrimination improvement of 
0.067 (p < 0.001). Moreover, the EFT was the strongest 
predictor of worsening disability at 1 year (OR: 2.13) and 
death at 30 days (OR: 3.29). The authors concluded that 
frailty is a risk factor for death and disability following 
TAVI and surgical AVR. A brief 4-item scale including 
lower-extremity weakness, cognitive impairment, anemia, 
and hypoalbuminemia outperformed other frailty scales 
and is recommended for use in this setting (Afilalo J et al, 
J Am Coll Cardiol 2017; 70:689-700   
EFFORTLESS Registry: the Subcutaneous ICD (S-
ICD) Remains Safe and Effective, With Low Incidence 
of Device Upgrade for Bradycardia, CRT, or ATP, and 
Low Rate of Implant Complications 
All 985 patients with S-ICD (mean age 48 years, 28% 
women, ejection fraction 43 ± 18%; 65% with a primary 
prevention indication) were followed for 3.1 ± 1.5 years; 
82 completed 5-year follow-up. The complication rate was 
4.1% at 1 month and 8.4% at 1 year. The 1-year 
complication rate trended toward improvement from the 
first to last quartile of enrollment (11.3% to 7.4%; p 
=0.06). Few device extractions occurred due to need for 
antitachycardia (n = 5), or biventricular (n = 4) or 
bradycardia pacing (n = 1). Inappropriate shocks occurred 
in 8.1% at 1 year and 11.7% after 3.1 years. At implant, 
99.5% of patients had a successful conversion of induced 
ventricular tachycardia/fibrillation. The 1- and 5-year rates 
of appropriate shock were 5.8% and 13.5%, respectively. 
Conversion success for discrete spontaneous episodes was 
97.4% overall (Boersma L et al, J Am Coll Cardiol 2017; 
70:830-841).   
CoreValve Evolut R FORWARD study: The Next-
Generation, Self-expanding Evolut R Valve is 
Clinically Safe and Effective for Treatment of Older 
Patients with Severe Aortic Stenosis (AS) 
TAVI with the next-generation self-expanding valve 
was attempted in 1,038 patients with symptomatic, severe 
AS (mean age 81.8 ± 6.2 years, 64.9% women, mean STS 
score 5.5 ± 4.5%, 33.9% frail). Repositioning of the valve 
was applied in 25.8% of patients. A single valve was 
implanted in 98.9% of patients. The mean aortic valve 
gradient was 8.5 ± 5.6 mmHg, and moderate or severe 
aortic regurgitation was 1.9% at discharge. All-cause 
mortality was 1.9%, and disabling stroke occurred in 1.8% 
at 30 days. The expected-to-observed early surgical 
mortality ratio was 0.35. A pacemaker was implanted in 
17.5% of patients (Grube E et al, J Am Coll Cardiol 2017; 
70:845-853).   
Gasping During Cardiopulmonary Resuscitation 
(CPR) is Independently Associated With a Higher 
Likelihood of 1-Year Survival With Favorable 
Neurological Status After Out-Of-Hospital Cardiac 
Arrest (OHCA)  
The rates of 1-year survival with a Cerebral 
Performance Category (CPC) score of ≤2 were 5.4% (98 
of 1,827) overall, and 20% (36 of 177) and 3.7% (61 of 
1,643) for individuals with and without spontaneous 
gasping or agonal respiration during CPR, respectively. In 
multivariable analysis, 1-year survival with CPC≤2 was 
independently associated with younger age (odds ratio - 
OR for 1 SD increment 0.57), gasping during CPR (OR: 
3.94), shockable initial recorded rhythm (OR: 16.50), 
shorter CPR duration (OR: 0.31), lower epinephrine 
dosage (OR: 0.47), and pulmonary edema (OR: 3.41). 
Gasping combined with a shockable initial recorded 
rhythm had a 57-fold higher OR of 1-year survival with 
CPC≤2 vs no gasping and no shockable rhythm (Debaty G 
et al, J Am Coll Cardiol 2017;135:1467-1476).   
N-Acetylcysteine (NAC) is an Effective and Safe 
Alternative to Currently Available Antithrombotic 
Agents to Restore Vessel Patency After Arterial 
Occlusion  
IV administration of NAC promotes lysis of arterial 
thrombi that are resistant to conventional approaches such 
as recombinant tissue-type plasminogen activator (rTPA), 
direct thrombin inhibitors, and antiplatelet treatments. 
Through in vitro and in vivo experiments, evidence was 
provided that the molecular target underlying the 
thrombolytic effects of NAC is principally the von 
Willebrand factor (VWF) that cross-link platelets in 
arterial thrombi. Coadministration of NAC and a 
nonpeptidic GpIIb/IIIa inhibitor further improved its 
thrombolytic efficacy, by accelerating thrombus 
dissolution and preventing rethrombosis. Thus, in a new 
large-vessel thromboembolic stroke model in mice, this 
cotreatment significantly improved ischemic lesion size 
and neurological outcome. Importantly, NAC did not 
worsen hemorrhagic stroke outcome, suggesting that it 
exerts thrombolytic effects without significantly impairing 
normal hemostasis (de Lizarrondo SM et al, Circulation 
2017;136:646-660).   
NACIAM Trial: High-Dose IV N-Acetylcysteine (NAC) 
Administered With Low-Dose IV Nitroglycerin is 
Associated With Reduced Infarct Size in Patients With 
STEMI Undergoing PCI 
The effects of IV high-dose NAC (29 g over 2 days) 
with background low-dose nitroglycerin (7.2 mg over 2 
days) on early cardiac MRI (CMR)–assessed infarct size 
were evaluated in 112 randomized patients with STEMI, 
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of whom 75 (37 in NAC group, 38 in placebo group) 
underwent early CMR. Median duration of ischemia 
pretreatment was 2.4 hours. Those randomized to NAC 
exhibited an absolute 5.5% reduction in CMR–assessed 
infarct size relative to placebo (median, 11%; vs 16.5%; 
P=0.02). Myocardial salvage was approximately doubled 
in the NAC group (60%) compared with placebo (27%; 
P<0.01) and median creatine kinase areas under the curve 
were 22 000 and 38 000 IU·h in the NAC and placebo 
groups, respectively (P=0.08) (Pasupathy S et al, 
Circulation 2017;136:894-903).  
Rising Pandemic of Obesity: Nearly 70% of the Deaths 
That were Related to High BMI were Due to 
Cardiovascular (CV) Disease, and >60% of Those 
Deaths Occurred Among Obese Persons   
In 2015, a total of 107.7 million children and 603.7 
million adults were obese. Since 1980, the prevalence of 
obesity has doubled in more than 70 countries and has 
continuously increased in most other countries. Although 
the prevalence of obesity among children has been lower 
than that among adults, the rate of increase in childhood 
obesity in many countries has been greater than the rate of 
increase in adult obesity. High BMI accounted for 4 
million deaths globally, nearly 40% of which occurred in 
persons who were not obese. More than two thirds of 
deaths related to high BMI were due to CV disease. The 
disease burden related to high BMI has increased since 
1990; however, the rate of this increase has been attenuated 
owing to decreases in underlying rates of death from CV 
disease (The GBD 2015 Obesity Collaborators, N Engl J 
Med 2017; 377:13-27).   
Declining Risk of Sudden Death (SD) in Heart Failure  
Analysis of data from 40,195 patients who had heart 
failure with reduced ejection fraction, enrolled in any of 12 
clinical trials (1995-2014), with 3583 sudden deaths 
reported, indicated that these patients were older, more 
often male, with an ischemic cause of heart failure and 
worse cardiac function, than those without SD. There was 
a 44% decline in the rate of SD across the trials (P=0.03). 
The cumulative incidence of SD at 90 days after 
randomization was 2.4% in the earliest trial and 1% in the 
most recent trial. The rate of SD was not higher among 
patients with a recent diagnosis of heart failure than among 
those with a longer-standing diagnosis (Shen L et al, N 
Engl J Med 2017; 377:41-51).   
Idarucizumab for Rapid, Durable & Safe Dabigatran 
Reversal 
Among 301 patients with uncontrolled bleeding (group 
A) and 202 who were to undergo an urgent procedure 
(group B) who received 5 g of i.v. idarucizumab, the 
median maximum percentage reversal of dabigatran was 
100%, on the basis of either the diluted thrombin time or 
the ecarin clotting time. In group A, 137 patients (45.5%) 
presented with gastrointestinal bleeding and 98 (32.6%) 
presented with intracranial hemorrhage; among the 
patients who could be assessed, the median time to the 
cessation of bleeding was 2.5 h. In group B, the median 
time to the initiation of the intended procedure was 1.6 h; 
periprocedural hemostasis was assessed as normal in 
93.4% of the patients, mildly abnormal in 5.1%, and 
moderately abnormal in 1.5%. At 90 days, thrombotic 
events had occurred in 6.3% of the patients in group A and 
in 7.4% in group B, and the mortality rate was 18.8% and 
18.9%, respectively. There were no serious adverse events 
(Pollack CV et al, N Engl J Med 2017; 377:431-441).  
ROOBY-FS Trial: Off-Pump CABG Led to Lower 
Rates of 5-Year Survival and Event-Free Survival 
Than On-Pump CABG  
Among 2203 patients randomly assigned to undergo 
either on-pump or off-pump CABG, the rate of death at 5 
years was 15.2% in the off-pump group vs 11.9% in the 
on-pump group (relative risk, 1.28; P=0.02). The rate of 
major adverse cardiovascular events at 5 years was 31% in 
the off-pump group vs 27.1% in the on-pump group 
(relative risk, 1.14; P=0.046). For the 5-year secondary 
outcomes, no significant differences were observed: for 
nonfatal MI, the rate was 12.1% in the off-pump group and 
9.6% in the on-pump group (P=0.05); for death from 
cardiac causes, the rate was 6.3% and 5.3%, respectively 
(P=0.29); for repeat revascularization, the rate was 13.1% 
and 11.9%, respectively (P=0.39); and for repeat CABG, 
the rate was 1.4% and 0.5%, respectively (P=0.02). 
(Shroyer AL et al, N Engl J Med 2017; 377:623-632).   
CANVAS Trials: Canagliflozin Had a Lower Risk of 
Cardiovascular (CV) Events Than Those Who 
Received Placebo But a Greater Risk of Amputation 
(Level of the Toe or Metatarsal)  
Among 10,142 participants with type 2 diabetes and 
high CV risk (mean age 63.3 years, 35.8% women, mean 
duration of diabetes 13.5 years, 65.6% with history of CV 
disease), randomly assigned to canagliflozin or placebo, 
the rate of the primary outcome (CV death, MI or stroke) 
was lower with canagliflozin than with placebo (occurring 
in 26.9 vs. 31.5 participants per 1000 patient-years; hazard 
ratio - HR, 0.86; P<0.001 for noninferiority; P=0.02 for 
superiority). A possible benefit of canagliflozin was shown 
with respect to the progression of albuminuria (HR, 0.73) 
and the composite outcome of a sustained 40% reduction 
in the estimated glomerular filtration rate, the need for 
renal-replacement therapy, or death from renal causes 
(HR, 0.60). Adverse reactions were consistent with the 
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previously reported risks associated with canagliflozin 
except for an increased risk of amputation (6.3 vs. 3.4 
participants per 1000 patient-years; HR, 1.97), primarily at 
the level of the toe or metatarsal (Neal B et al; N Engl J 
Med 2017; 377:644-657).   
CLOSE Trial: Among Patients With a Recent 
Cryptogenic Stroke Attributed to PFO With an 
Associated Atrial Septal Aneurysm or Large 
Interatrial Shunt, the Rate of Stroke Recurrence was 
Lower Among those Assigned to PFO Closure  
Among 663 PFO patients (16-60 years old), followed 
for a mean of 5.3±2.0 years, no stroke occurred among the 
238 patients in the PFO closure group, whereas stroke 
occurred in 14 of the 235 patients in the antiplatelet-only 
group (hazard ratio, 0.03; P<0.001). Procedural 
complications from PFO closure occurred in 14 patients 
(5.9%). The rate of atrial fibrillation was higher in the PFO 
closure group than in the antiplatelet-only group (4.6% vs. 
0.9%, P=0.02). The number of serious adverse events did 
not differ significantly between the treatment groups 
(P=0.56). Stroke occurred in 3 of 187 patients assigned to 
oral anticoagulants and in 7 of 174 patients assigned to 
antiplatelet therapy alone (Mas J-L et al, N Engl J Med 
2017; 377:1011-1021).    
RESPECT Trial: Among Adults With a Cryptogenic 
Ischemic Stroke, Closure of a PFO was Associated with 
a Lower Rate of Recurrent Ischemic Strokes Than 
Medical Therapy Alone During Extended Follow-Up  
Among 980 patients (mean age, 45.9 years), followed 
for a median of 5.9 years, recurrent stroke occurred in 18 
patients in the PFO closure group and in 28 patients in the 
medical-therapy group, resulting in rates of 0.58 and 1.07 
events per 100 patient-years, respectively (hazard ratio 
with PFO closure vs medical therapy, 0.55; P=0.046 by the 
log-rank test). Recurrent ischemic stroke of undetermined 
cause occurred in 10 patients in the PFO closure group and 
in 23 patients in the medical-therapy group (hazard ratio, 
0.38; P=0.007). Venous thromboembolism (which 
comprised events of pulmonary embolism and deep-vein 
thrombosis) was more common in the PFO closure group 
than in the medical-therapy group (Saver JL et al, N Engl 
J Med 2017; 377:1022-1032).   
REDUCE Study: In PFO Patients With a Cryptogenic 
Stroke, the Risk of Ischemic Stroke was Lower Among 
Those Assigned to PFO Closure/ However, PFO 
Closure was Associated With Higher Rates of Device 
Complications and Atrial Fibrillation  
Among 664 PFO patients (mean age, 45.2 years, 81% 
with moderate or large interatrial shunts), over 3.2 years, 
clinical ischemic stroke occurred in 6 of 441 patients 
(1.4%) in the PFO closure group and in 12 of 223 patients 
(5.4%) in the antiplatelet-only group (hazard ratio, 0.23; 
P=0.002). The incidence of new brain infarctions was 
significantly lower in the PFO closure group than in the 
antiplatelet-only group (22 patients - 5.7% vs 20 patients - 
11.3%; relative risk, 0.51; P=0.04), but the incidence of 
silent brain infarction did not differ significantly between 
the study groups (P=0.97). Serious adverse events 
occurred in 23.1% in the PFO closure group and in 27.8% 
in the antiplatelet-only group (P=0.22). Serious device-
related adverse events occurred in 6 patients (1.4%) in the 
PFO closure group, and AF occurred in 29 patients (6.6%) 
after PFO closure (Søndergaard L et al, N Engl J Med 
2017; 377:1033-1042).    
CANTOS Trial: Antiinflammatory Therapy Targeting 
Interleukin-1β With Canakinumab at a s.c. Dose of 150 
mg Every 3 Months Led to a Significantly Lower Rate 
of Recurrent Cardiovascular Events Than Placebo, 
Independent of Lipid-Level Lowering 
Among 10,061 patients with previous MI and a hsCRP 
>2 mg/l, randomized to 3 doses of canakinumab, a 
therapeutic monoclonal antibody targeting interleukin-1β, 
or placebo, at 48 months the median reduction from 
baseline in the hs-CRP was 26 percentage points greater in 
the group that received the 50-mg dose of canakinumab, 
37 percentage points greater in the 150-mg group, and 41 
percentage points greater in the 300-mg group than in the 
placebo group. Canakinumab did not reduce lipid levels 
from baseline. At a median of 3.7 years, the incidence rate 
for the primary end point (nonfatal MI, nonfatal stroke, or 
CV death) was 4.50 events per 100 person-years in the 
placebo group, 4.11 in the 50-mg group (hazard ratio-HR 
0.93; p=NS), 3.86 in the 150-mg group (HR 0.85; 
p=0.021), and 3.90 in the 300-mg group (HR 0.86; 
p=0.031). The 150-mg dose, but not the other doses, met 
the threshold for statistical significance for the primary and 
secondary end points (HR 0.83; P=0.005). Canakinumab 
was associated with a higher incidence of fatal infection 
than was placebo. There was no significant difference in 
all-cause mortality. Interestingly, lung cancer mortality 
was lower with canakinumab than with placebo (Ridker 
PM et al, N Engl J Med 2017; 377:1119-1131).  
 
DETO2X–SWEDEHEART Trial: Routine Oxygen Use 
in Patients With Suspected Myocardial Infarction 
Without Hypoxemia did not Reduce 1-Year Mortality 
Among 6629 patients with suspected MI and an oxygen 
saturation of >90%, randomized to oxygen or ambient air, 
the primary end point of death from any cause within 1 
year after randomization occurred in 5% of patients (166 
of 3311) assigned to oxygen and in 5.1% of patients (168 
of 3318) assigned to ambient air (hazard ratio, 0.97; 
76 
 
 
P=0.80). Rehospitalization with MI within 1 year occurred 
in 126 patients (3.8%) assigned to oxygen and in 111 
patients (3.3%) assigned to ambient air (HR, 1.13; P=0.33) 
(Hofmann R et al, N Engl J Med 2017; 377:1240-1249). 
 
Meta-Analysis of Trials Comparing an Early vs a 
Delayed Invasive Strategy in Patients Presenting With 
Non-ST Elevation Acute Coronary Syndromes (NSTE-
ACS): An Early Invasive Strategy Might Reduce 
Mortality in High-Risk, but not in all Other, Patients 
Analysis of 8 trials (n=5324 NSTE-ACS patients) with 
a median follow-up of 6 months, indicated that overall, 
there was no significant mortality reduction in the early 
invasive group compared with the delayed invasive group 
HR 0.81; p=0.0879). In pre-specified analyses of high-risk 
patients, there was lower mortality with an early invasive 
strategy in patients with elevated cardiac biomarkers at 
baseline (HR 0.761), diabetes (0.67), a GRACE risk score 
more than 140 (0.70), and aged 75 years older (0.65), 
although tests for interaction were inconclusive. (Jobs A et 
al, Lancet 2017; 390 (10096):737-746).  
 
Meta-Analysis of Fibrinolysis Trials: Differences Exist 
Among Various Fibrinolytics in STEMI / Alteplase 
(Accelerated Infusion), Tenecteplase, and Reteplase 
Should be Considered Over Streptokinase and Non-
Accelerated Infusion of Alteplase / The Addition of 
Glycoprotein IIb-IIIa Inhibitors to Fibrinolytic 
Therapy Should be Discouraged  
According to 40 studies involving 128 071 patients 
treated with 12 different fibrinolytic regimens, compared 
with accelerated infusion of alteplase with parenteral 
anticoagulants as background therapy, streptokinase and 
non-accelerated infusion of alteplase were significantly 
associated with an increased risk of all-cause mortality 
(risk ratio -RR 1.14 for streptokinase plus parenteral 
anticoagulants; RR 1.26 for non-accelerated alteplase plus 
parenteral anticoagulants). No significant difference in 
mortality risk was recorded between accelerated infusion 
of alteplase, tenecteplase, and reteplase with parenteral 
anticoagulants as background therapy. For major bleeding, 
a tenecteplase-based regimen tended to be associated with 
lower risk of bleeding compared with other regimens (RR 
0.79). The addition of glycoprotein IIb/IIIa inhibitors to 
fibrinolytic therapy increased the risk of major bleeding by 
1.27–8.82-times compared with accelerated infusion 
alteplase plus parenteral anticoagulants (RR 1.47 for 
tenecteplase plus parenteral anticoagulants plus 
glycoprotein inhibitors; RR 1.88 for reteplase plus 
parenteral anticoagulants plus glycoprotein inhibitors) 
(Jinatongthal P et al, Lancet 2017;390:747-759).   
Bioresorbable Vascular Scaffolds (BVS) are Associated 
With Increased Rates of Composite Device-Oriented 
Adverse Events and Device Thrombosis at 2 Years and 
Between 1 and 2 Years of Follow-Up Compared With 
Metallic Everolimus-Eluting Stents (EES) 
Analysis of 7 trials with 5583 patients randomly 
assigned to Absorb BVS (n=3261) or metallic EES 
(n=2322) and followed up for 2 years, indicated that BVS 
had higher 2-year relative risks of the device-oriented 
composite endpoint than did EES (9.4% vs 7.4%; relative 
risk -RR 1.29), driven by increased rates of target vessel-
related MI (5.8% vs 3.2%; RR 1.68, p=0.0003) and 
ischemia-driven target lesion revascularization (5.3% 
vs3.9%; RR 1.40, p=0.0090) with BVS, with non-
significant differences in cardiac mortality. Cumulative 2-
year incidence of device thrombosis was higher with BVS 
than with EES (2.3% vs 0.7%; RR 3.35, p<0.0001). 
Analysis between 1 and 2 years also showed higher rates 
of the device-oriented composite endpoint (3.3% vs 1.9%; 
RR 1.64, p=0.0376) and device thrombosis (0.5% vs none, 
p<0·0001) in BVS-treated patients than in EES-treated 
patients (Ali ZA et al, Lancet 2017;390: 760-772).  
 
In Patients with Ischemic (ICM) or Non-Ischemic 
Cardiomyopathy (NICM), Primary Prevention With 
ICD Therapy Versus Conventional Care Reduced the 
Incidence of Sudden and All-Cause Death  
Meta-analysis of 11 trials involving 8716 patients (4 
comprising 1781 patients with NICM, 6 comprising 4414 
patients with ICM, and 1 comprising 2521 patients with 
both types of cardiomyopathy), indicated that over a mean 
of 3.2 years, there was an overall reduction in all-cause 
mortality, from 28.26% with conventional care to 21.37% 
with ICD therapy (hazard ratio -HR, 0.81; P= 0.043). The 
magnitude of reduction was similar in the cohorts with 
non-ischemic (HR, 0.81) and ischemic (HR, 0.82) disease, 
although the latter estimate did not reach statistical 
significance. The rate of sudden death fell from 12.15% 
with conventional care to 4.39% with ICD therapy (HR, 
0.41), with a similar magnitude of reduction in patients 
with ischemic (HR, 0.39) and those with non-ischemic 
disease (HR, 0.44). Noncardiac and any cardiac deaths did 
not differ significantly by treatment (Kołodziejczak M et 
al, Ann Intern Med 2017;167:103-111)  
 
EPIC Study in 10 European Countries: Coffee 
Drinking was Associated With Reduced Risk for Death 
from Various Causes  
Among 521,330 persons enrolled in EPIC, over a mean 
of 16.4 years, 41,693 deaths occurred. Compared with non-
consumers, participants in the highest quartile of coffee 
consumption had lower all-cause mortality (men: HR, 
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0.88; P for trend< 0.001; women: HR, 0.93; P = 0.009). 
Inverse associations were also observed for digestive 
disease mortality for men (HR, 0.41; P < 0.001) and 
women (HR, 0.60; P < 0.001). Among women, there was 
a significant inverse association of coffee drinking with 
circulatory (HR, 0.78; P < 0.001) and cerebrovascular 
disease mortality (HR, 0.70; P = 0.002) and a positive 
association with ovarian cancer mortality (HR, 1.31; P = 
0.015). Also, higher coffee consumption was associated 
with lower serum alkaline phosphatase; alanine amino-
transferase; aspartate aminotransferase; γ-glutamyl-
transferase; and, in women, C-reactive protein, 
lipoprotein(a), and glycated hemoglobin levels (Gunter MJ 
et al, Ann Intern Med 2017; 167:236-247).  
 
SPRINT: Intensive Systolic Blood Pressure (SBP) 
Lowering Increased Risk for Incident Chronic Kidney 
Disease (CKD) Events, but this was Outweighed by 
Cardiovascular and All-Cause Mortality Benefits  
The difference in adjusted mean eGFR between the 
intensive and standard groups was −3.32 mL/min/1.73 m2 
at 6 months, was −4.50 mL/min/1.73 m2 at 18 months, and 
remained relatively stable thereafter. An incident CKD 
event occurred in 3.7% of participants in the intensive 
group and 1% in the standard group at 3-year follow-up, 
with a hazard ratio of 3.54. The corresponding percentages 
for the composite of death or cardiovascular event were 
4.9% and 7.1% at 3-year follow-up, with a hazard ratio of 
0.71 (Beddhu S et al, Ann Intern Med 2017;167:375-383). 
 
Cardiac Resynchronization Therapy (CRT) in the US: 
From 2003 to 2013, the Severity of Comorbid 
Conditions Increased and a Rising Trend was 
Observed in the Rate of Periprocedural Complications 
Among Patients Undergoing CRT  
From 2003 to 2013, 439,010 CRT implantations were 
performed in the U.S. (median age 72; 71% male). Overall, 
6.1% had at least one complication. During the study 
period, comorbidity index and overall complication rate 
increased (P = 0.002 and P = 0.01, respectively). Mortality 
and length of stay showed no significant trend. Predictors 
of complications included: age >65, female sex (OR: 1.19), 
Deyo–Charlson Comorbidity Index, and elective 
admission (OR: 0.61). (Hosseini S-M et al, Eur Heart J 
2017;38: 2122–2128). 
 
Optogenetics for Biological Management of 
Arrhythmias: Brief Local Epicardial Illumination of 
the Optogenetically Modified Adult Rat Heart Allowed 
Contact- and Shock-Free Termination of Ventricular 
Arrhythmias  
Optogenetics is a novel, biological technique allowing 
electrical modulation in a specific, reversible and trauma-
free manner using light-gated ion channels. Systemic 
delivery of cardiotropic adeno-associated virus vectors, 
encoding the light-gated depolarizing ion channel red-
activatable channelrhodopsin (ReaChR), resulted in global 
cardiomyocyte-restricted transgene expression in adult 
Wistar rat hearts allowing ReaChR-mediated 
depolarization and pacing. Ventricular tachyarrhythmias 
(VTs) were induced in the optogenetically modified hearts 
by burst pacing in a Langendorff setup, followed by 
programmed, local epicardial illumination. A single 470-
nm light pulse terminated 97% of monomorphic and 57% 
of polymorphic VTs vs 0% without illumination, as 
assessed by ECG recordings. Optical mapping showed 
significant prolongation of voltage signals just before 
arrhythmia termination. Pharmacological action potential 
duration (APD) shortening almost fully inhibited light-
induced arrhythmia termination indicating an important 
role for APD in this process (Nyns ECA et al, Eur Heart J 
2017;38:2132–2136). 
 
EVITA: Vitamin D did not Reduce Mortality in 
Patients With Advanced Heart Failure (HF), While 
there was a Greater Need for Mechanical Support (MS) 
As 25-hydroxyvitamin D (25OHD) levels <75 nmol/L 
are associated with an increase in mortality risk, 400 HF 
patients with vitamin D deficiency were randomized to 
4000 IU vitamin D daily or placebo for 3 years. Mortality 
was not different in patients receiving vitamin D (19.6%; 
n = 39) or placebo (17.9%; n = 36). The need for MS was 
however greater in patients assigned to vitamin D (15.4%, 
n = 28) vs. placebo (9%, n = 15; HR: 1.96; P = 0.031) 
(Zittermann A et al, Eur Heart J 2017;38:2279-86).  
 
Extreme High High-Density Lipoprotein (HDL) 
Cholesterol is Paradoxically Associated With High 
Mortality in Men and Women / a New U-Shaped Curve 
/It All Comes down to HDL Functionality, not Quantity 
Among 52 268 men and 64 240 women during 745,452 
person-years of follow-up, number of deaths from any 
cause were 5619 (mortality rate, 17.1/1000 person-years) 
in men and 5059 (mortality rate, 12.1/1000 person-years) 
in women. The association between HDL cholesterol 
concentrations and all-cause mortality was U-shaped for 
both men and women, with both extreme high and low 
concentrations being associated with high all-cause 
mortality risk. The concentration of HDL cholesterol 
associated with the lowest all-cause mortality was 
73 mg/dL in men and 93 mg/dL in women. When 
compared with the groups with the lowest risk, the multi-
factorially adjusted hazard ratios – HRs for all-cause 
mortality were 1.36 for men with HDL cholesterol of 97–
115 mg/dL and 2.06 for men with HDL cholesterol 
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≥116 mg/dL. For women, corresponding HRs were 1.10 
for HDL cholesterol of 116–134 mg/dL and 1.68 for HDL 
cholesterol ≥135 mg/dL (Madsen CM et al, Eur Heart J 
2017;38:2478-86).  
 
Individuals Who Work Long Hours (≥55 per Week) are 
More Likely to Develop Atrial Fibrillation (AF) Than 
Those Working Standard Hours (35–40 h/Week) 
Among 85 494 working men and women (mean age 
43.4 years) with no recorded AF, over 10 years, 1061 new 
cases of AF were identified (10-year cumulative incidence 
12.4 per 1000). Individuals working long hours had a 1.4-
fold increased risk of AF compared with those working 
standard hours (HR = 1.42, P = 0.003). There was no 
significant heterogeneity between the cohort-specific 
effect estimates and the finding remained after excluding 
participants with coronary heart disease or stroke at 
baseline or during the follow-up (N = 2006, HR = 1.36, 
P = 0.0180). Adjustment for potential confounding factors, 
such as obesity, risky alcohol use and high blood pressure, 
had little impact on this association (Kivimaki M et al, Eur 
Heart J 2017;38: 2621-28).  
 
Bromocriptine Enhances LV Recovery and Reduces 
Morbidity/Mortality in Peripartum Cardiomyopathy 
(PPCM) Patients  
Among 63 PPCM patients with LVEF ≤35% assigned 
to short-term (1W: bromocriptine, 2.5 mg, 7 days) or long-
term bromocriptine (8W: 5 mg for 2 weeks followed by 
2.5 mg for 6 weeks) in addition to standard heart failure 
therapy, LVEF increased from 28 ± 10% to 49 ± 12% in 
the 1W-group, and from 27 ± 10% to 51 ± 10% in the 8W-
group. Full-recovery (LVEF ≥ 50%) was present in 52% of 
the 1W- and in 68% of the 8W-group with no differences 
in secondary end points between both groups. The risk 
within the 8W-group to fail full-recovery after 6 months 
tended to be lower. No patient in the study needed heart 
transplantation, LV assist device or died (Hilfiker-Kleiner 
D et al, Eur Heart J 2017;38: 2671-79).  
 
SOURCE-3: A Low Complication Rate and Mortality 
at 1 Year with the Latest Generation Transcatheter 
Balloon-Expandable Valve  
The SAPIEN 3 was implanted in 1946 patients (mean 
age 81.6 ± 6.7 years, 52% male). At 1 year, all-cause 
mortality was 12.6%, CV mortality 8%, stroke 3.1%, 
disabling stroke 1.4%, and rate of new pacemakers 13.2%. 
Causes of death were 62% CV and 38.0% non-CV, with 
heart failure (13.4%) and pulmonary complications 
(12.7%) being the main reasons for fatal outcomes. 
Multivariable analysis identified NYHA Class IV and 
renal insufficiency as predictors of mortality, while higher 
BMI’s improved survival. Severe (zero) and moderate 
paravalvular leakage (2.6%) was rare at 1 year (Wendler O 
et al, Eur Heart J 2017;38: 2717-26).  
 
ADVANCE Study: Continued Valve Durability of the 
Self-Expanding Bioprosthesis at 5 Years With Low 
Rates of Reinterventions and Valve Dysfunction 
Among 1015 patients (mean age 81 years, mean logistic 
EuroSCORE 19.3 ± 12.3%), at 5 years, the rate of all-cause 
mortality was 50.7%, and major stroke 5.4%. Hemodyna-
mic measures remained consistent with a mean gradient of 
8.8 ± 4.4 mmHg (n = 198) and an effective orifice area of 
1.7 ± 0.4 cm2 (n = 123). Aortic regurgitation (AR) 
decreased over time and among paired patients dropped 
from 12.8% to 8% moderate AR at 5 years (n = 125). Of 
the 860 patients with echocardiographic data or a reinter-
vention after 30 days, there were 22 (2.6%) patients with 
valve dysfunction & 10 (1.2%) with a reintervention >30 
days (Gerckens U et al, Eur Heart J 2017; 38;2729-38).  
 
Important Review and Other Articles  
Vitamin D and CV disease (Al Mheid I et al, J Am Coll 
Cardiol 2017;70:89-100), Cardiovascular effects of 
cocaine (Havakuk O et al, J Am Coll Cardiol 2017;70:101-
113), 2017 AHA/ACC Focused Update of the Guideline 
for the Management of Patients With Valvular Heart 
Disease (Nishimura RA et al, J Am Coll Cardiol 
2017;70:252-289), Alcohol septal ablation for obstructive 
hypertrophic cardiomyopathy (J Am Coll Cardiol 
2017;70:481-488 & 489-494), High-sensitivity cardiac 
troponin (Twerenbold R et al, J Am Coll Cardiol 
2017;70:996-1012), Defibrillation of VF (Nichol G et al, J 
Am Coll Cardiol 2017;70:1496-1509), 2017 ACC/AHA/ 
HFSA Guideline Update for the Management of 
Heart Failure (Yancy CW et al, J Am Coll Cardiol 
2017; 70:776-803). Atrial cardiomyopathy (Guichard 
J-B & Nattel S, J Am Coll Cardiol 2017; 70:756-765), 
Modifiable risk factors for AF (Lau DH et al, 
Circulation 2017; 136: 583-596), Conduction 
disturbances after TAVI (Auffret V et al, Circulation 
2017; 136: 1049-1069), Acute coronary syndromes 
(Crea F & Libby P, Circulation 2017;136: 1155-
1166), Esophageal injury caused by ablation of AF 
(Kapur F et al, Circulation 2017;136: 1247-1255), 
Mechanical vs bioprosthetic aortic valves (Head SJ et 
al, Eur Heart J 2017;28:2183-91), ESC guidance for 
use of PCSK-9 inhibitors (Landmesser U et al, Eur 
Heart J 2017; 29:2245-55), Cardiac manifestations of 
sarcoidosis (Birnie DH et al, Eur Heart J 2017; 
38:2663-70), 2017 ESC Guidelines for the 
management of valvular heart disease (Baumgartner 
H et al, Eur Heart J 2017;38:2739-91.  
